Therapeutics News and Research

RSS

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

The hematology journal BLOOD published today a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch.

22 Aug 2012

FDA committee to review NPS’ Gattex NDA in October

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for Gattex (teduglutide) will be discussed at the Gastrointestinal Drugs Advisory Committee meeting scheduled for October 16, 2012.

22 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases

Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.

17 Aug 2012

Radiosensitivity molecular signature can lead to better radiation therapy decisions for breast cancer

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

16 Aug 2012

Low adropin levels may increase risk of metabolic disease

Working with a national team of researchers, a scientist from the Florida campus of The Scripps Research Institute has shown for the first time a link between low levels of a specific hormone and increased risk of metabolic disease in humans.

16 Aug 2012

3SBio files APX001 IND application with SFDA in China

Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that its partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug (IND) application for APX001, also known as SSS07, with the State Food and Drug Administration (SFDA) in China.

16 Aug 2012

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121.

15 Aug 2012

Combination of obatoclax and flavopiridol triggers multiple myeloma cell death

Researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory and animal experiments involving a new combination therapy for multiple myeloma, the second most common form of blood cancer.

15 Aug 2012

Medicine brand choices: an interview with Dr Lynn Weekes

In Australia, people will only be offered a choice when the brands are bioequivalent, meaning they contain the same active ingredient (i.e. the chemical in the medicine that makes it work) and have been proven to work the same in the body.

15 Aug 2012

Novel method identifies new oncogene that contributes to development of cancer

A team of researchers at Case Western Reserve University School of Medicine, led by Dr. Mark W. Jackson, have developed a novel method to identify genes that, when overexpressed, make normal cells behave like cancer cells.

14 Aug 2012

Carnegie Mellon University awarded CURE grant by the Pennsylvania Department of Health

Pennsylvania Department of Health Executive Deputy Secretary Michael Wolf today presented a Commonwealth Universal Research Enhancement Program, or CURE, grant to Carnegie Mellon University. The $983,783 grant will be used for a two-year research project focused on cancer treatment technologies.

13 Aug 2012

FDA extends PDUFA action date for NPS Gattex NDA

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has received a communication from the U.S. Food and Drug Administration extending the Prescription Drug User Fee Act action date for its New Drug Application for Gattex (teduglutide) by three months to December 30, 2012.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

FDA approved drug to treat Ph- acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults.

10 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).

9 Aug 2012

Global market value of Alzheimer's disease therapeutics could soar to $8 billion: GEN

The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN).

8 Aug 2012

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Chemotherapy kills tumor cells, but it also wreaks havoc on the rest of the body. A team of researchers led by Igor Roninson of the South Carolina College of Pharmacy just reported the discovery of a new class of drugs that reduces the adverse effects of cellular damage from chemotherapy.

8 Aug 2012

Therapeutics News and Research

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

FDA committee to review NPS’ Gattex NDA in October

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases

Radiosensitivity molecular signature can lead to better radiation therapy decisions for breast cancer

Low adropin levels may increase risk of metabolic disease

3SBio files APX001 IND application with SFDA in China

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

Combination of obatoclax and flavopiridol triggers multiple myeloma cell death

Medicine brand choices: an interview with Dr Lynn Weekes

Novel method identifies new oncogene that contributes to development of cancer

Carnegie Mellon University awarded CURE grant by the Pennsylvania Department of Health

FDA extends PDUFA action date for NPS Gattex NDA

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

FDA approved drug to treat Ph- acute lymphoblastic leukemia

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Global market value of Alzheimer's disease therapeutics could soar to $8 billion: GEN

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News